Evidence map›Paper›PMID 27530994›Full record

Observational studyClinical and experimental nephrology2017

Efficacy of urinary midkine as a biomarker in patients with acute kidney injury.

Hiroki Hayashi, Waichi Sato, Tomoki Kosugi, Kunihiro Nishimura, Daisuke Sugiyama, Naoko Asano, Shinya Ikematsu, Kimihiro Komori, Kimitoshi Nishiwaki, Kenji Kadomatsu and 3 more

Abstract readComparative StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical and experimental nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Hiroki HayashiDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan. hhayashi@fujita-hu.ac.jp.
Waichi SatoDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tomoki KosugiDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kunihiro NishimuraDepartment of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center, Osaka, Japan.
Daisuke SugiyamaDepartment of Preventive Medicine and Public Health, Keio University, Tokyo, Japan.
Naoko AsanoDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shinya IkematsuDepartment of Bioresources Engineering, Okinawa National College of Technology, Okinawa, Japan.
Kimihiro KomoriDepartment of Vascular Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kimitoshi NishiwakiDepartment of Anesthesiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kenji KadomatsuDepartment of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Seiichi MatsuoDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shoichi MaruyamaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yukio YuzawaDepartment of Nephrology, Fujita Health University School of Medicine, 1-98 Dengakugakuho, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Nagoya University · JPFujita Health University Hospital · JPKeio University · JPNational Cerebral and Cardiovascular Center · JPNational Institute of Technology Okinawa College · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe mortality and morbidity associated with acute kidney injury (AKI) remains high, despite advances in interventions. A multifunctional heparin-binding growth factor, midkine (MK), is involved in the pathogenesis of ischemic kidney injury. However, the clinical relevance of MK has not yet been elucidated. The present study investigated whether urinary MK can serve as a novel biomarker of AKI.

methodsWe initially compared the predictive value of MK with other urinary biomarkers, including N-acetyl-β-D-glucosaminidase (NAG), interleukin (IL)-18, and neutrophil gelatinase-associated lipocalin (NGAL), for the detection and differential diagnosis of established AKI (549 patients). Subsequently, the reliability of MK for the early detection of AKI was prospectively evaluated in 40 patients undergoing elective abdominal aortic aneurysm surgery. Urine samples were obtained at baseline, the period of aortic cross-clamping and declamping, the end of the surgery, and on post-operative day 1.

resultsThe areas under the receiver operating characteristic curves for the diagnosis of AKI in various kidney diseases were 0.88, 0.70, 0.72, and 0.84 for MK, NAG, IL-18, and NGAL, respectively. When the optimal cutoff value of urinary MK was set at 11.5 pg/mL, the sensitivity and specificity were 0.87 and 0.85, respectively. In the second study, urinary MK peaked at the period of aortic declamping, about 1 h after cross-clamping in patients with AKI. Interestingly, the rise of MK in AKI patients was very precipitous compared with other biomarker candidates.

conclusionUrinary MK was prominent in its ability to detect AKI and may allow the start of preemptive medication.

Indexed as

Acute Kidney InjuryAdultAgedAortic Aneurysm, AbdominalArea Under CurveBiomarkersCase-Control StudiesCross-Sectional StudiesDiagnosis, DifferentialEarly DiagnosisEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedMidkineBiomarkersMDK protein, humanMidkineNerve Growth FactorsAcute kidney injuryAcute tubular necrosisBiomarkerMidkine

Identifiers

PMID27530994
OpenAlexW2511468498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.